Video
Dr. Stephen Savage discusses molecular testing and unmet needs in prostate cancer
Author(s):
“We really try to be careful about testing, especially when it's a potential burden of costs on the patient. What we really look at is where it's going to have an impact,” says Stephen J. Savage, MD.
Video Player is loading.
In this interview, Stephen J. Savage, MD, discusses current research he’s working on, the role of molecular testing in prostate cancer as well as unmet needs in treating the disease. Savage is director of minimally invasive urology at the Medical University of South Carolina, Charleston.
Related Videos
Expert discusses the NMIBC trials landscape
John Gore, MD, on bladder preservation in muscle–invasive bladder cancer
Joy Maulik, CRNP, on the importance of genetic testing in prostate cancer
5 key trial insights from AUA 2025
Experts discuss expanding use of vibegron for OAB
John Michael DiBianco, MD, on silicone vs polyurethane stents for patients with kidney stones
Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
Khurshid Ghani, MD, on trial of stent omission following ureteroscopy
Karyn S. Eilber, MD, shares her reaction to genitourinary syndrome of menopause guidelines
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Related Content
